Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease
NL-OMON28041Not yet recruiting
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of vedolizumab in Crohn's disease and autoimmune colitis, sponsored by None. Primary endpoint: Correlation between vedolizumab trough level and disease activity. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
vedolizumab
03
Conditions
Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on NL-OMON28041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28041.